Niagen Bioscience Surpasses Q4 EPS Estimate by 100%, Revenues Reach $33.8M
Niagen Bioscience reported Q4 adjusted EPS of $0.03, a 100% surprise to consensus $0.02, matching prior-year EPS. Revenue rose 16.2% year-over-year to $33.84 million, surpassing estimates by 8.8%, though shares have declined 23.4% YTD.
1. Q4 Earnings and Revenue Beat
Niagen Bioscience delivered adjusted Q4 EPS of $0.03, doubling the $0.015 year-ago level and topping the $0.02 consensus by 100%. Revenue of $33.84 million grew 16.2% from $29.13 million a year earlier and exceeded estimates by 8.8%.
2. Year-to-Date Share Performance
Shares have declined 23.4% year-to-date despite consistent quarterly outperformance over four straight periods. The Medical – Biomedical and Genetics industry ranks in the bottom 44% of peers, reflecting sector headwinds.
3. Outlook and Analyst Estimates
Consensus forecasts call for $0.05 EPS and $35.1 million revenue next quarter. Estimate revisions trended downward pre-release, contributing to a Sell rating and signaling potential near-term pressure.